Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo
Important Safety Information | Patient Site
Prescribing Information
    • Why NovoSeven® RT?
    • Pharmacology
    • Congenital Hemophilia A & B with Inhibitors
    • Breakthrough Bleeds
    • Acquired Hemophilia
    • Congenital Factor VII Deficiency
    • Glanzmann's Thrombasthenia
    • Hospital Overview
    • Clinical Pathway for Emergent Bleeds
    • Clinical Pathway for Acquired Hemophilia
    • Dosing Tools & Reference
    • Infusion Preparation
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo

Indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and in adults with acquired hemophilia.

Prescribing Information
Important Safety Information | Patient Site

Talk to us about NovoSeven® RT.

The #1 prescribed bypassing agent used in hospitals1,a

The established bleed control and perioperative efficacy of NovoSeven® RT across four indications makes it the most used rFVIIa in hospitals:1,2

The #1 prescribed bypassing agent used in hospitals1,a

The established bleed control and perioperative efficacy of NovoSeven® RT across five indications makes it the most used rFVIIa in hospitals1,2:

aBased on ADIVO data collected between 2022 and 2023.1

Actor portrayal

"I'll never forget my first patient. When I saw a prolonged aPTT, I knew where to turn for a fast treatment."2

"I'll never forget my first patient. When I saw a prolonged aPTT, I knew where to turn for a fast treatment."2


93% N=69

Congenital hemophilia with inhibitors, as seen in the adept 2 clinical trial.2,3

See study design

95% N=139

Acquired hemophilia4
(first-line treatment)

See study design

93% N=70

Congenital Factor VII
deficiency2,5

See study design

94% N=92

Glanzmann’s
thrombasthenia2

See study design

Explore interactive dosing tools

See recommendations and use the calculator tool for perioperative and breakthrough bleed dosing across 5 approved indications.2

Go to NovoSeven® RT dosing tools

NovoSeven® RT for your hospital:
the broadest range of protectionb

Proven effective for bleed resolution and surgery across 5 indications.2

CHAwI

CHBwI

Acquired
hemophilia

GT

CFVIId

NovoSeven®RT2
(coagulation Factor VIIa, recombinant)

Light blue triangle and dark blue circle
Light blue triangle and dark blue circle
Light blue triangle and dark blue circle
Light blue triangle and grey hexagon
Light blue triangle and grey hexagon

SEVENFACT®6
[coagulation factor VIIa (recombinant)-jncw]

Light blue triangle
Light blue triangle
Red triangle and blue circle
Red triangle and blue circle
Red triangle and blue circle

FEIBA®7
(anti-inhibitor coagulant complex or pd-aPCC)

Light blue triangle, dark blue circle, grey square, and grey hexagon
Light blue triangle, dark blue circle, grey square, and grey hexagon
Red triangle and blue circle
Red triangle and blue circle
Red triangle and blue circle

Obizur®8
[antihemophilic factor (recombinant), porcine sequence]

Red triangle and blue circle
Red triangle and blue circle
Light blue triangle
Red triangle and blue circle
Red triangle and blue circle

Blue triangle

= bleed treatment;

Blue circle

= perioperative management

Grey square

= routine prophylaxis

Grey hexagon

= pediatric indication

Bleed resolution and surgery indications table
Bleed resolution and surgery indications legend

Not intended to be a comparison of efficacy or safety.

bIndicated for bleed control and surgery in 5 bleeding disorders.2
c
For patients aged 12 years and older.6
d
Obizur® is contraindicated in patients with congenital hemophilia A with inhibitors.8

CHAwI=congenital hemophilia A with inhibitors;
CHBwI=congenital hemophilia B with inhibitors;
CFVIId=congenital factor VII defi ciency; GT=Glanzmann’s Thrombasthenia with refractoriness to platelets; pd-aPCC=plasma-derived activated prothrombin complex concentrate


NovoSeven® RT offers
features to support hospital use2

NovoSeven® RT vial and prefilled syringe

Appropriate for a variety of hospital uses:

  • Faster to infuse compared with FEIBA® and Obizur®2,6,7,e
  • NovoSeven® RT has one dosing regimen for patients with CHwI regardless of bleed severity - That consistent dosing may lead to predictable utilization2
  • Ability to administer via continuous infusion for perioperative management
  • Recombinant safety and low rate of thrombotic adverse events based on clinical trials and registry data2,f
    • The most common and serious adverse reaction in clinical trials are thrombotic events2,f

Efficient for your hospital pharmacy:

  • Low-volume dosing and compact packaging to help maximize space
  • Room temperature storage up to 77˚Fg
  • Each vial comes with a prefilled syringe, meaning no extra steps to fill a syringe with diluenth
    • Available in 1-mg, 2-mg, 5-mg, and 8-mg vials with everything needed for reconstitution is in 1 box

eAdminister NovoSeven® RT as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.1 FEIBA should be injected or infused intravenously at a rate that does not exceed 10 units per kg of body weight per minute. For a dose of 75 U/kg, this equates to an infusion time of 7.5 minutes. Administer Obizur® intravenously at a rate of 1 to 2 mL per minute. For a 75 kg patient receiving a dose of 200 u/kg, this corresponds to an infusion time of 15 to 30 minutes.2,7,8
f
0.2% in CHwI bleeds, 4% of patients with acquired hemophilia, <0.2% in GT bleeds, and 0.8% in patients with CFVIId bleeds.2
g
Prior to reconstitution, store NovoSeven® RT powder and histidine diluent between 36-77˚F. After reconstitution, store NovoSeven® RT either at room temperature or refrigerated for up to 3 hours. Do not freeze reconstituted NovoSeven® RT or store in syringes.2
h
Compared with reconstitution using histidine vials.

In the ER: be prepared for acute & emergent bleeding with NovoSeven® RT

NovoSeven® RT box
  • In situations where a patient does not bring their own clotting factor concentrate, MASAC recommends emergency departments have ready access to factor replacement product within 1 hour upon a patient’s arrival.8
  • MASAC also recommends rFVIIa as a first option to treat acute bleeding episodes in patients with CHAwI on emicizumab—FEIBA® (pd-aPCC) should be avoided if possible.9
  • For patients with CHAwI on emicizumab, duration of FEIBA® therapy should be minimized. Prolonged usage of FEIBA® for >24 hours with doses above 100 units/kg/day may be associated with thrombosis and TMA.9


Explore clinical pathways for
CHwI & acquired hemophilia

Is your hospital ready to treat emergent bleeds for CHwI patients?

A severe joint bleed doesn’t just mean danger today—delayed treatment of emergent joint bleeds in the CHwI population may result in cumulative damage.13

Take steps to see if your emergency department is prepared to stop bleeds & their consequences.

Explore the emergent bleeds clinical pathway

Let's go

Actor Portrayal

Early diagnosis is crucial for treating acquired hemophilia—do you know the signs?

Acquired hemophilia (AH) is a rare and often idiopathic autoimmune condition that can cause severe and even fatal bleeding in a variety of patients.14

It's time to equip every department with resources and information to rapidly diagnose and treat AH.

Explore the AH clinical pathway

Let's go

Actor Portrayal

Study design
Vial icon

Lentz, et al
adept™2 phase 3 trial 

Patients randomized: Patients ≥12 years of age with hemophilia A with inhibitors (N=66) or hemophilia B with inhibitors (N=6) who have experienced at least 5 bleeds during treatment prior to entering the trial. 

Study design: A 12-month, international, multicenter, randomized, double-blind, active-controlled, crossover, confirmatory phase 3 trial. Primarily done in the home setting, treatment of bleeding episodes were randomized, either treated with 1 to 3 doses of vatreptacog alfa (340 bleeding episodes) at 80 mcg/kg or 1 to 3 doses of NovoSeven® RT (227 bleeding episodes) at 90 mcg/kg.

Primary endpoint: Effective bleed control, which was defined as no additional treatment needed (other than the original medication) within 12 hours after first dose. 

 

Secondary endpoint: Effective and sustained bleed control at 1 and 2 days after initial dose, number of doses of trial product for each bleed, and changes in pain assessment. 

Sumner, et al
Compassionate use programs, the Hemostasis and Thrombosis Research Society (HTRS) registry, and independent published reports

Patients considered: Patients diagnosed with acquired hemophilia from compassionate and emergency use programs (N=61), the HTRS (N=9) and independent published reports (N=69).

Study design: Data were extracted from a review of experiences with recombinant FVIIa for the treatment of acquired hemophilia in compassionate and emergency use programs, the Hemostasis and Thrombosis Research Society (HTRS) registry, and independent published reports. Efficacy was evaluated similarly but not identically between compassionate use programs, the HTRS registry, and published reports.

Efficacy of NovoSeven® RT is based on pooled data from the NovoSeven® RT compassionate and emergency use programs (1988–1999), the Hemostasis and Thrombosis Research Society (HTRS) registry, and independent published reports from January 1999 to September 2005. The analysis includes 182 bleeding episodes in 139 patients; NovoSeven® RT was used as first-line and salvage therapy in 103 and 73 episodes, respectively. The percentage of effectiveness noted includes episodes that were evaluated as effective or partially effective.

Published literature, compassionate use trials, and the Hemophilia and Thrombosis Research Society (HTRS) Registry

Patients considered: Data was collected from published literature, compassionate use trials, and the HTRS for patients with congenital factor VII deficiency (N=70) treated with NovoSeven® RT.

Study design: NovoSeven® RT was used as treatment in 124 bleeding episodes, surgeries, or prophylaxis regimens. Dosing ranged from 6 to 98 mcg/kg administered every 2 to 12 hours (except for prophylaxis [doses administered from 2 times per day up to 2 times per week]). Patients were treated with an average of 1 to 10 doses. Treatment was effective if bleeding stopped or the physician rated the treatment as effective.

Glanzmann’s Thrombasthenia Registry (GTR)

Patients considered: Data was collected from the GTR in patients with Glanzmann’s thrombasthenia (N=218). 

Study design: Adjudicator-assessed effectiveness of treatment regimens in patients with GT (N=218) in all severe bleeding episodes and all surgical procedures (N=1073) based on review of Glanzmann’s Thrombasthenia Registry (GTR) data unblinded to investigator-coded efficacy. Efficacy was evaluated on a 2-point scale (clinical assessment of success or failure of treatment regimen as a whole, blinded and unblinded to investigator-coded outcome) including 92 patients treated with NovoSeven® RT for 266 bleeding episodes and 77 patients treated for 160 surgical procedures.

NovoSeven® RT vials

Need administration information?

See how to administer
Patient in hospital bed

Looking for more professional education?

Start here

Selected Important Safety Information for NovoSeven® RT

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.

References

  1. Data on file as of 2023. Novo Nordisk Inc; Plainsboro, NJ.
  2. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
  3. Lentz SR, Ehrenforth S, Abdul Karim F, et al; adept™2 investigators. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014;12(8):1244-1253.
  4. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia. 2007;13(5):451-461.
  5. Mariani G, Napolitano M, Dolce A, et al. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. Thromb Haemost. 2013;109:238–247.
  6. FEIBA [package insert]. Westlake Village, CA: Baxalta US Inc; 2024.
  7. Obizur [package insert]. Westlake Village, CA: Baxalta US Inc; 2024.
  8. National Hemophilia Foundation. MASAC Guidelines for Emergency Department Management of Individuals with Hemophilia and Other Bleeding Disorders, #257. 2019.
  9. National Hemophilia Foundation. Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia A With and Without Inhibitors, #268. New York, NY: National Hemophilia Foundation; 2022.
  10. Levy GG, Asikanius E, Kuebler P, et al. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost. 2019;17(9):1470-1477.
  11. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80(5):773-778.
  12. Lusher JM, Roberts HR, Davignon G, et al; and rFVIIa Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4(6):790-798.
  13. Salek SZ, Benson GM, Elezovic I, et al. The need for speed in in the management of haemophilia patients with inhibitors. Haemophilia. 2011;17(1):95-102.
  14. Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2020;94(4):566-575.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

NovoSeven® is a registered trademark and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2025 Novo Nordisk All rights reserved. US24NSVN00014 May 2025

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials